Tiziana Life Sciences Ltd cash flow to debt ratio of -2.82K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Tiziana Life Sciences Ltd's free cash flow has decreased 942.29% from $-1.23M last year to $-12.87M, signaling decreasing performance

Tiziana Life Sciences Ltd's debt to equity ratio is -0.34, signaling that the company spent its equity and risk bankruptcy.

Tiziana Life Sciences Ltd's debt has increased relative to shareholder equity from 0.03 last year to -0.34 today, signaling weakened financials

Tiziana Life Sciences Ltd has a net cash position, so leverage is healthy.

Tiziana Life Sciences Ltd earns at least as much interest as it pays. Interest obligations are fully covered.

Tiziana Life Sciences Ltd has insufficient data to evaluate this check.

Tiziana Life Sciences Ltd's short-term liabilities of $11.21M exceed its short-term assets of $8.55M, signaling financial risk

Tiziana Life Sciences Ltd's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Tiziana Life Sciences Ltd's return on equity of 1.87K%, is higher than 15.00%, indicating good performance

Tiziana Life Sciences Ltd's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Tiziana Life Sciences Ltd had positive net income in only 0 out of 5 years, indicating unstable earnings

Tiziana Life Sciences Ltd has negative free cash flow, indicating the company is burning cash rather than generating it

Tiziana Life Sciences Ltd has negative free cash flow, indicating cash burn

Tiziana Life Sciences Ltd's yearly earnings has decreased 55.37% since last year from $-11.86M to $-18.43M, signaling decreasing performance

Tiziana Life Sciences Ltd's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 1.28K% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Tiziana Life Sciences Ltd has insufficient revenue history to calculate 3-year revenue CAGR.

Tiziana Life Sciences Ltd had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Tiziana Life Sciences Ltd had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Tiziana Life Sciences Ltd has insufficient data to evaluate this check.

Tiziana Life Sciences Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tiziana Life Sciences Ltd is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Tiziana Life Sciences Ltd has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Tiziana Life Sciences Ltd has insufficient data to evaluate this check.

Tiziana Life Sciences Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tiziana Life Sciences Ltd has negative shareholder equity; price-to-book is not meaningful and the check fails

Tiziana Life Sciences Ltd has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue